Novo Nordisk and Eli Lilly Compete in GLP-1 Pill Market Ahead of Medicare Coverage
Novo Nordisk (NVO) and Eli Lilly & Co. (LLY) are intensifying their competition for the GLP-1 pill market ahead of July's anticipated Medicare coverage, which could make millions of seniors eligible to access these weight-loss drugs at a reduced cost. Novo reported over 3 million prescriptions for its Wegovy pill in five months, while Lilly noted significant growth in Foundayo prescriptions without disclosing exact figures.
Topics: GLP-1 drugs Medicare eligibility obesity treatment pharma competition